(Q37263863)

19 August 2017

1 reference

title

Facts and controversies in the use of trastuzumab in the adjuvant setting (English)

1 reference

19 August 2017

1 reference

2

Evandro de Azambuja

0 references

Martine Piccart-Gebhart

series ordinal

4

object named as

Martine J Piccart-Gebhart

0 references

Fátima Cardoso

series ordinal

3

object named as

Fatima Cardoso

1 reference

19 August 2017

Phuong Dinh

1

1 reference

19 August 2017

publication date

9 September 2008

1 reference

Nature Clinical Practice Oncology

19 August 2017

published in

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

11

1 reference

19 August 2017

page(s)

645-654

1 reference

CASE 2. Acquired hypertrichosis: a rare paraneoplastic syndrome in various cancers

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Tailoring adjuvant treatments for the individual breast cancer patient.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

HER-2/neu and topoisomerase IIalpha in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Adjuvant trastuzumab for breast cancer: the other side of the coin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Economic evaluation of the prevention and treatment of breast cancer--present status and open issues

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1219

7 January 2021

Identifiers

DOI

10.1038/NCPONC1219

1 reference

19 August 2017

1 reference